Parse Biosciences, formerly Split Biosciences, is a biotechnology startup dedicated to providing scalable single-cell sequencing solutions.
Parse Biosciences is on a mission to accelerate progress in human health and scientific research.
Parse Biosciences was founded in 2018 by Alex Rosenberg and Charlie Roco. The company is headquartered in Seattle, Washington.
Parse’s product portfolio includes the Evercode Whole Transcriptome Mega, which can profile up to 1,000,000 cells in parallel, and the Evercode Whole Transcriptome Mini, a kit used to profile up to 10,000 cells in parallel for studies of smaller scale.
Parse also supplies a computational pipeline which generates an experimental report along with a gene-cell count matrix and other processed data that integrates into existing open source tools, such as Seurat and Scanpy.
Parse partnered with Decode Sciences to provide its single-cell sequencing solution to Australia and New Zealand. Shortly afterwards, Parse announced a distribution agreement with Research Instruments Pte Ltd to expand its availability to Singapore, Thailand, Malaysia and Vietnam.
Parse is backed by Marshall Wace, Janus Henderson Investors, Bioeconomy Capital, Soleus Capital, Logos Capital, and others. The company raised $41.5M in Series B round on Feb 15, 2022. This brings Parse's total funding to $50.5M to date.